Miguel Pastrana MD, Presenter: Speakers bureau, Alexion Pharmaceuticals, Incs

Emilio Ojeda MD, PhD, Abstract Co-Author: Consultant, Alexion Pharmaceuticals, Inc Speakers Bureau, Alexion Pharmaceuticals, Inc

Carlota Perez MD, Abstract Co-Author: Nothing to Disclose

Beatriz Brea-Alvarez, Abstract Co-Author: Nothing to Disclose

Daniel Morillo MD, Abstract Co-Author: Nothing to Disclose

Concepcion Gonzalez MD, PhD, Abstract Co-Author: Nothing to Disclose

The purpose of this exhibit is: 1. To report the experience of our Center by presenting a review of radiological findings of 56 Paroxysmal Nocturnal Hemoglobinuria (PNH) patient cases. 2. To describe the main MR imaging findings in thrombotic complications of PNH patients. 3. To evaluate the iron overload that in some PNH cases could be underestimated and needs chelation therapy 4. To describe the programmed protocoled evaluation previous to consider Eculizumab treatment.

-From 1970 to November 2013, 56 patients with the PNH clone have been evaluated in our hospital. In the last five years, MRI studies were performed in our PNH patients in acute complications (9 patients) or as a programmed protocol evaluation previous to considering and/or evaluating Eculizumab treatment (14 patients). -Different protocols designed for the study of this pathology -Thrombosis was found in four cases. In three patients, these findings implied initiating Eculizumab therapy -Minor ischemic brain changes were displayed by three patients. -We evaluate and quantify kidney and liver iron concentrations in seven patients with PNH, treated with Eculizumab, and to correlate the image with laboratory findings.

http://abstract.rsna.org/uploads/2014/14005172/14005172_lf77.pdf

Pastrana, M, Ojeda, E, Perez, C, Brea-Alvarez, B, Morillo, D, Gonzalez, C, Paroxysmal Nocturnal Hemoglobinuria and Eculizumab Therapy Evaluated by Magnetic Resonance Imaging.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14005172.html